Andere Sprachen G1 Therapeutics, Inc.

Aktien

A2DR0J

US3621LQ1099

GTHX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 19.04.2024			% 5 Tage	% 1. Jan.
4.11 ^USD	-1.44%		-9.67%	+34.75%

28.02.	G1 Therapeutics, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
28.02.	G1 THERAPEUTICS, INC. : Bewertung von Wedbush zum Kaufen erhalten	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024	17.04.
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference	04.04.
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01.04.
G1 THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)	04.03.
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01.03.
G1 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.02.
Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q4 Revenue $14.9M	28.02.
G1 Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2024	28.02.
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights	28.02.
G1 Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28.02.
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference	27.02.
G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024	15.02.
Top Midday Decliners	13.02.
Caution Ahead of Key Inflation Data Weighs on Exchange-Traded Funds, Equity Futures Pre-Bell Tuesday	13.02.
G1 Therapeutics Gets Nod for Continuing Breast Cancer Study But CEO Notes Lack of 'Positive Interim Analysis'; Shares Drop Premarket	13.02.
G1 Therapeutics Gets Continuation Recommendation From Data Monitoring Committee for Phase 3 Breast Cancer Study	13.02.
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee	12.02.
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee	12.02.
Life Sciences Ontario Announces Recipients of 2024 LSO Awards	16.01.
G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference	08.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen G1 Therapeutics, Inc.

Aktien

A2DR0J

US3621LQ1099

GTHX

Andere Sprachen

Filter